News & Updates

Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.

Continuous and intermittent use of tapinarof cream 1% once daily (QD) for up to 1 year is effective in patients with mild-to-severe plaque psoriasis, without serious safety concerns, according to a study. In addition, it has shown durable efficacy and a remittive effect of at least 4 months off therapy.

The status of sentinel lymph nodes (SLN) can help predict the course of the disease in patients with clinical stage IIB/C cutaneous melanoma, suggests a study.

The risk of retinal disease seems to be greater among patients with alopecia areata (AA), according to a nationwide population-based cohort study.

Patients with generalized pustular psoriasis (GPP) suffer from a heavier burden of comorbidities than the general population and comparators with psoriasis vulgaris (PV), a new study has found.

Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.

The use of dupilumab in the treatment of atopic dermatitis appears to benefit patients who have dark skin types more than those who have light skin types, as shown in a study.

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.